drugset / Trial / NCT02584140
Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women
Phase 4
Completed
136 enrolled
University of California, Los Angeles
AIDS Project Los Angeles · collabCalifornia HIV/AIDS Research Program · collabLos Angeles County Department of Public Health · collabUniversity of California, San Diego · collab
NaSingle-groupOpen-labelPrevention
Summary
The purpose of this study is to test a program that uses drug level monitoring, text messaging ("iTAB") and personalized counseling with HIV prevention services, including PrEP (medicine that can help prevent HIV infection when taken daily).
Timeline
- Start
- 2016-05
- Primary completion
- 2019-05-15
- Completion
- 2019-06-14
Publications
- Anderson KM, Blumenthal J, Jain S, Sun X, Amico KR, Landovitz R, Zachek CM, Morris S, Moore DJ, Stockman JK. The impact of intimate partner violence on PrEP adherence among U.S. Cisgender women at risk for HIV. BMC Public Health. 2024 May 31;24(1):1461. doi: 10.1186/s12889-024-18946-4.
- Blumenthal J, Landovitz R, Jain S, He F, Kofron R, Ellorin E, Ntim GM, Stockman JK, Corado K, Rivet Amico K, Moore DJ, Morris S. Pre-Exposure Prophylaxis Perspectives, Sociodemographic Characteristics, and HIV Risk Profiles of Cisgender Women Seeking and Initiating PrEP in a US Demonstration Project. AIDS Patient Care STDS. 2021 Dec;35(12):481-487. doi: 10.1089/apc.2021.0114.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tenofovir disoproxil fumarate | Small molecule | — | Oral |
| Subject | emtricitabine | Other / unclassified | — | Oral |
Indications
No indication recorded.